After reaching a record high in 2021, venture capital dollars have tailed off in 2022. That said, a few biopharma hotbeds have still seen sizeable launches and subsequent rounds.
When it comes to Series A funding by geographical region, the usual suspects have again cornered the market.
The Genetown region of Massachusetts has drawn the highest-funded new companies, while Biotech Bay (San Francisco and Northern California) has also seen a smattering of significant Series As. BioSpace highlights a few of the most lucrative launch rounds of 2022.
